


Val-Ala-PABC-Exatecan trifluoroacetate

Cat. No.:	HY-147095A
CAS No.:	2928571-45-1
Molecular Formula:	C ₄₂ H ₄₄ F ₄ N ₆ O ₁₀
Molecular Weight:	868.83
Target:	Drug-Linker Conjugates for ADC; Topoisomerase
Pathway:	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (57.55 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.1510 mL	5.7549 mL	11.5097 mL
	5 mM		0.2302 mL	1.1510 mL	2.3019 mL
	10 mM		0.1151 mL	0.5755 mL	1.1510 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Val-Ala-PABC-Exatecan trifluoroacetate is a Drug-Linker Conjugates for ADC, consisting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor, HY-13631). Val-Ala-PABC-Exatecan trifluoroacetate can be used for ADC molecules synthesis, such as Mal-PEGn-amide-va-Exatecan ^[1] .
IC₅₀ & Target	Camptothecins

REFERENCES

[1]. Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA